FEB 25, 2014
Comprehensive Ophthalmology, Retina/Vitreous
The John A. Moran Eye Center at the University of Utah has announced that Voyant Biotherapeutics, a company formed out of its Center for Translational Medicine (CTM), has signed an exclusive R&D Collaboration Agreement with Allergan to develop new ocular disease treatments, primarily new AMD treatments.
“This relationship is special in that it is a true collaboration between CTM, Voyant, and Allergan scientists,” said Gregory Hageman, Ph.D., John A. Moran Presidential Professor, Department of Ophthalmology and Visual Sciences, and Executive Director of Moran’s CTM. “The CTM’s incredibly talented, multidisciplinary research team and its unique cadre of resources—including multiple, well-characterized patient cohorts, a repository of human eyes derived from greater than 6,000 donors, and extensive population-based records housed within the Utah Population Database—have provided a robust understanding of AMD and a solid platform upon which to conduct this collaboration.”
"We are extremely excited about the significance of this collaboration,” commented Dr. Randall Olson, CEO of the Moran Eye Center. “This collaboration could not have happened without the generous contributions of hundreds of people supporting the CTM in its quest to find new treatments for the prevention and treatment of AMD and other ocular diseases. This collaboration is further testament to the groundbreaking research that is being conducted at the Moran.”